Calliditas Therapeutics (NASDAQ:CALT) reported quarterly losses of $(0.88) per share. This is a 163.47 percent decrease over losses of $(0.33) per share from the same period last year. The company reported $28.43 million in sales this quarter. This is a 55.21 percent increase over sales of $18.32 million the same period last year.
Calliditas Therapeutics Q1 EPS $(0.88) Down From $(0.33) YoY, Sales $28.43M Up From $18.32M YoY
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.